Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: A potentiality for cancer gene therapy

Cancer Letters

Volumn 128, Issue 1, 1998, Pages 47-53

  Kimura, Masaki ^a   Tagawa, Masatoshi ^a   Takenaga, Keizo ^a   Kondo, Fukuo ^b   Yamaguchi, Taketo ^b   Saisho, Hiromitsu ^b   Nakagawara, Akira ^a   Sakiyama, Shigeru ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

AsPC 1; Gene therapy; Interleukin 2; Interleukin 4; Pancreatic cancer

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CARCINOGENICITY; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; MONOCYTE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETROVIRUS; TUMOR VOLUME;

ANIMALS; CELL DIVISION; GENE THERAPY; HUMANS; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0032486226     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00050-0     Document Type: Article

References (26)

1. Tepper R.I., Mulé J.J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5:1994;153-164.
2. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:1990;397-403.
3. Gastl G., Finstad C.L., Guarini A., Bosl G., Gilboa E., Bander N.H., Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 52:1992;6229-6236.
4. Cignetti A., Guarini A., Carbone A., Forni M., Cronin K., Forni G., Gansbacher B., Foa R. Transduction of the IL-2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL-2 receptor expression. J. Natl. Cancer Inst. 86:1994;785-791.
5. Tepper R.I., Pattengale P.K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:1989;503-512.
6. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:1991;713-716.
7. Tepper R.I., Coffman R.L., Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 257:1992;548-551.
8. Wei M.X., Tamiya T., Hurford R.K. Jr., Boviatsis E.J., Tepper R.I., Chiocca E.A. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum. Gene Ther. 6:1995;437-443.
9. Mullen C.A., Coale M.M., Levy A.T., Stetler-Stevenson W.G., Liotta L.A., Brandt S., Blaese R.M. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 52:1992;6020-6024.
10. Porgador A., Tzehoval E., Katz A., Vadai E., Revel M., Feldman M., Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:1992;3679-3686.
11. Sun W.H., Kreisle R.A., Phillips A.W., Ershler W.B. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res. 52:1992;5412-5415.
12. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:1993;3539-3543.
13. Sanda M.G., Ayyagari S.R., Jaffee E.M., Epstein J.I., Clift S.L., Cohen L.K., Dranoff G., Pardoll D.M., Mulligan R.C., Simons J.W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151:1994;622-628.
14. Chen W.H., Horoszewicz J.S., Leong S.S., Shimano T., Penetrante R., Sanders W.H., Berjian R., Douglass H.O., Martin E.W., Chu T.M. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro. 18:1982;24-34.
15. Miller A.D., Rosman G.J. Improved retroviral vectors for gene transfer and expression. BioTechniques. 7:1989;980-990.
16. Yamada G., Kitamura Y., Sonoda H., Harada H., Taki S., Mulligan R.C., Osawa H., Diamantstein T., Yokoyama S., Taniguchi T. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J. 6:1987;2705-2709.
17. Yasukawa K., Hirano T., Watanabe Y., Muratani K., Matsuda T., Nakai S., Kishimoto T. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6:1987;2939-2945.
18. Yokota T., Otsuka T., Mosmann T., Banchereau J., DeFrance T., Blanchard D., Vries J.E.D., Lee F., Arai K. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor1 activities and T-cell- and mast-cell-stimulating activities. Proc. Natl. Acad. Sci. USA. 83:1986;2061-2065.
19. Miyatake S., Otsuka T., Yokota T., Lee F., Arai K. Structure of the chromosomal gene for granulocyte-macrophage colony stimulating factor: comparison of the mouse and human genes. EMBO J. 4:1985;2561-2568.
20. Takatsuki F., Okano A., Suzuki C., Chieda R., Takahara Y., Hirano T., Kishimoto T., Hamuro J., Akiyama Y. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J. Immunol. 141:1988;3072-3077.
21. Gunji Y., Tagawa M., Matsubara H., Takenaga K., Shimada H., Kondo F., Suzuki T., Nakajima K., Aoki T., Asano T., Ochiai T., Isono K., Kageyama H., Nakamura Y., Sakiyama S. Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response. Int. J. Cancer. 66:1996;135-139.
22. Watanabe T., Fuchimoto S., Iwagaki H., Nonaka Y., Nezu M., Nishina T., Marutaka M., Susaki K., Naomoto Y., Shiiki S., Matsubara N., Orita K. Anti-proliferative effect of combined tumour necrosis factor-α and interferon-α on human pancreatic cancer in vitro and in vivo. Anticancer Res. 13:1993;1501-1506.
23. Peplinski G.R., Tsung K., Meko J.B., Norton J.A. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery. 118:1995;185-191.
24. Alosco T., Croy B.A., Gansbacher B., Wang H.Q., Rao U., Bankert R. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. Cancer Immunol. Immunother. 36:1993;364-372.
25. Hara I., Nguyen H., Takechi Y., Gansbacher B., Chapman P.B., Houghton A.N. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int. J. Cancer. 61:1995;253-260.
26. Li Y., Newby S.A., Johnston J.V., Hellström K.E., Chen L. Protective immunity induced by B7/CD28-costimulated γδ-T cells to the EL-4 lymphoma in allogenic athymic mice. J. Immunol. 155:1995;5705-5710.